Is there evidence that treatment of Fabry Disease—either with migalastat-based chaperone therapy or ERT—is capable of mitigating progression of GI symptoms?

Is there evidence that treatment of Fabry Disease—either with migalastat-based chaperone therapy or ERT—is capable of mitigating progression of GI symptoms?

CLICK HERE FOR CME CREDIT

Is there evidence that treatment of Fabry Disease—either with migalastat-based chaperone therapy or ERT—is capable of mitigating progression of GI symptoms? 

Created by

CMEducation Resources IQ&A Fabry Disease Diagnostic Intelligence Zone

Presenter

Claire Zar-Kessler, MD

Claire Zar-Kessler, MD

Medical Director, Pediatric Neurogastroenterology Program
Instructor, Harvard Medical School
Mass General Hospital for Children
Boston, MA